title: Mood stability in Parkinson disease following deep brain stimulation: a 6-month prospective follow-up study.
abstract: BACKGROUND
  Deep brain stimulation for Parkinson disease has been associated with psychiatric adverse effects including anxiety, depression, mania, psychosis, and suicide.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the safety of deep brain stimulation in a large Parkinson disease clinical practice.
  
  
  METHODS
  Patients approved for surgery by the Mayo Clinic deep brain stimulation clinical committee participated in a 6-month prospective naturalistic follow-up study. In addition to the Unified Parkinson's Disease Rating Scale, stability and psychiatric safety were measured using the Beck Depression Inventory, Hamilton Depression Rating Scale, and Young Mania Rating scale. Outcomes were compared in patients with Parkinson disease who had a psychiatric history to those with no co-morbid psychiatric history.
  
  
  RESULTS
  The study was completed by 49 of 54 patients. Statistically significant 6-month baseline to end-point improvement was found in motor and mood scales. No significant differences were found in psychiatric outcomes based on the presence or absence of psychiatric comorbidity.
  
  
  CONCLUSIONS
  Our study suggests that patients with Parkinson disease who have a history of psychiatric co-morbidity can safely respond to deep brain stimulation with no greater risk of psychiatric adverse effect occurrence. A multidisciplinary team approach, including careful psychiatric screening ensuring mood stabilization and psychiatric follow-up, should be viewed as standard of care to optimize the psychiatric outcome in the course of deep brain stimulation treatment.
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Amit
authors.initials: A
authors.lastname: Chopra
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Osama A
authors.initials: OA
authors.lastname: Abulseoud
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Shirlene
authors.initials: S
authors.lastname: Sampson
authors.affiliation: Department of Neurosurgery, Mayo Clinic, Rochester, MN.
authors.forename: Kendall H
authors.initials: KH
authors.lastname: Lee
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN.
authors.forename: Bryan T
authors.initials: BT
authors.lastname: Klassen
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Julie A
authors.initials: JA
authors.lastname: Fields
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN.
authors.forename: Joseph Y
authors.initials: JY
authors.lastname: Matsumoto
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN.
authors.forename: Andrea C
authors.initials: AC
authors.lastname: Adams
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Cynthia J
authors.initials: CJ
authors.lastname: Stoppel
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Geske
authors.affiliation: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN. Electronic address: mfrye@mayo.edu.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Frye
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D015897:Comorbidity; D046690:Deep Brain Stimulation / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000209:etiology / Q000517:prevention & control* / Q000523:psychology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology* / Q000628:therapy*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents